Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First annual report of the Austrian CML registry.
Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry. Schmidt S, et al. Among authors: woll e. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. doi: 10.1007/s00508-010-1450-x. Epub 2010 Oct 11. Wien Klin Wochenschr. 2010. PMID: 20936366
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zubel A, Schmoll HJ. Arnold D, et al. Among authors: woll e. Ann Oncol. 2008 Aug;19(8):1442-1449. doi: 10.1093/annonc/mdn150. Epub 2008 Apr 25. Ann Oncol. 2008. PMID: 18441330 Free article. Clinical Trial.
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C. Lordick F, et al. Among authors: woll e. Br J Cancer. 2010 Feb 2;102(3):500-5. doi: 10.1038/sj.bjc.6605521. Epub 2010 Jan 12. Br J Cancer. 2010. PMID: 20068568 Free PMC article. Clinical Trial.
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study.
Brunner C, Arvandi M, Marth C, Egle D, Baumgart F, Emmelheinz M, Walch B, Lercher J, Iannetti C, Wöll E, Pechlaner A, Zabernigg A, Volgger B, Castellan M, Andraschofsky OT, Markl A, Hubalek M, Schnallinger M, Puntscher S, Siebert U, Schönherr S, Forer L, Bruckmoser E, Laimer J. Brunner C, et al. Among authors: woll e. J Clin Oncol. 2025 Jan 10;43(2):180-188. doi: 10.1200/JCO.24.00171. Epub 2024 Aug 20. J Clin Oncol. 2025. PMID: 39163561 Free PMC article.
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.
Ludwig H, Melchardt T, Schweitzer I, Sormann S, Schreder M, Andel J, Hartmann B, Zojer N, Schöffmann L, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Knop S, Greil R. Ludwig H, et al. Among authors: woll e. EJHaem. 2024 May 17;5(3):494-504. doi: 10.1002/jha2.925. eCollection 2024 Jun. EJHaem. 2024. PMID: 38895059 Free PMC article.
Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
Huemer F, Weiss L, Regitnig P, Winder T, Schmitt CA, Thaler J, Wöll E, Greil R. Huemer F, et al. Among authors: woll e. ESMO Open. 2024 Apr;9(4):102973. doi: 10.1016/j.esmoop.2024.102973. Epub 2024 Mar 19. ESMO Open. 2024. PMID: 38507896 Free PMC article. No abstract available.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Ludwig H, et al. Among authors: woll e. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. Am J Hematol. 2024. PMID: 38425185 Clinical Trial.
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer.
Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, Faber G, Gockel I, Köberle D, Lorenzen S, Möhler M, Pritzkuleit R, Stahl M, Thuss-Patience P, Wöll E, Zander T, Maschmeyer G; Germany Society of Hematology and Medical Oncology (DGHO, Austrian Society of Hematology and Oncology (OeGHO), Swiss Society of Hematology (SSH), Swiss Society of Medical Oncology (SGMO); in collaboration with the Arbeitsgemeinschaft Internistische Onkologie (AIO) of the German Cancer Society. Lordick F, et al. Among authors: woll e. Gastric Cancer. 2024 Jan;27(1):6-18. doi: 10.1007/s10120-023-01424-y. Epub 2023 Oct 17. Gastric Cancer. 2024. PMID: 37847333 Free PMC article.
119 results